Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, BioLife Solutions, Inc. reported revenue of $96M, up 28.9% year over year. Operating margin was -17.3% and net margin -4.8%, on a free-cash-flow margin of 11.1% with capital expenditure at 9.9% of revenue. Every figure is computed directly from BLFS's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $96M | -17.3% | -4.8% |
| FY2024 | $75M | -6.0% | -27.0% |
| FY2023 | $68M | -25.3% | -100.0% |
| FY2022 | $76M | -7.8% | -183.4% |
| FY2021 | $119M | -29.5% | -7.5% |
How does BLFS compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: A · ACHR · AEHR · AERG · AEVA · AIRI
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.